Completed PHASE3 INTERVENTIONAL NCT00373464

Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Surgery

Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Gynaecologic Surgery With Expected Need of Post-operative Opioids

Sponsor: Merck Sharp & Dohme LLC

Conditions Hysterectomy Ovariectomy Postoperative Pain Tubal Excision

Interventions etoricoxib

Updated 6 times since 2017 Last updated: Jun 30, 2011 Started: Mar 31, 2006 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hysterectomy and Ovariectomy and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Ullevaal University Hospital
University of Oslo

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway